Latest total assets for TRRI: $7.8K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Alzex Neuropharma's total assets stands at $7.8K as of June 2024. That compares with $7.6K in the prior-year period — up 3.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Alzex Neuropharma reported $7.8K in total assets versus $7.6K a year earlier — a 3.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
That compares with $7.6K in the prior-year period — up 3.2% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Alzex Neuropharma's total assets evolved across reporting periods, while the comparison chart places TRRI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.